This review evaluated the effect of oral contraceptives on bone mineral density. The authors concluded that there is good evidence of a positive effect in perimenopausal women and fair evidence of a positive effect in hypothalamic oligo/amenorrhoeic premenopausal women. Poor reporting of review methods and reliance on a few small randomised controlled trials mean that these results should be interpreted with caution.
evidence, based on study design; criteria included sample size, randomisation, specific inclusion criteria, adequate follow-up and blinding. The levels of evidence ranged from 5 (expert opinion without explicit critical appraisal, or based on physiology, bench research or first principles) to 1a (systematic review with homogeneity of RCTs).
The authors did not state how the quality assessment was performed.
Data extraction
The authors did not state how the data were extracted for the review, or how many reviewers performed the data extraction.
The results from individual studies were classified as having a positive effect, no effect or a negative effect on the outcomes of interest. The results from controlled trials tended to be reported as changes from baseline in the review.
Methods of synthesis
How were the studies combined?
The studies were combined in a narrative, grouped by population (healthy premenopausal, 'hypothalamic' oligo/amenorrhoeic premenopausal, anorexic premenopausal or perimenopausal) and outcome (measurement of BMD or biochemical measurement of bone metabolism).
How were differences between studies investigated?
Differences in study design were explored.
Results of the review
Seventy-five studies were reviewed: 11 RCTs (n=544), 28 cohort studies (n=3,256), 32 cross-sectional studies (n=19,547), 3 case series (n=94) and 1 case report.
BMD.
Healthy premenopausal women: 46 studies, including 4 RCTs (n=246), were reviewed. All 4 RCTs reported no effect on BMD for OCs compared with baseline controls. Three of the 16 cohort studies, 7 of the 25 cross-sectional studies, and the case series reported positive effects of OCs on BMD; other studies reported no effect or negative effects.
Oligo/amenorrhoeic premenopausal women: 10 studies, including 3 RCTs (n=122), were reviewed. Two of the RCTs reported a positive effect of OCs on BMD; one compared with placebo and one compared to baseline. The third RCT reported no increase in BMD from baseline with oestrogen treatment. Five of the 6 cohort studies reported positive effects of OCs on BMD, while the case series reported negative effects. Anorexic premenopausal women: 8 studies, including 3 RCTs (n=159), were reviewed. All 3 RCTs reported no effect of OCs on BMD. The 2 cross-sectional studies reported positive effects of OCs on BMD; other studies (2 cohort studies and 1 case series) reported no effect or negative effects.
